|
KMID : 1007520200290060837
|
|
Food Science and Biotechnology
2020 Volume.29 No. 6 p.837 ~ p.844
|
|
|
Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial
|
|
Kim Jin-Joo
Cho Kum-Sun
Kim Joo-Sung
Jung Hyun-Chae
Kim Bum-Sik
Park Myeong-Soo
Ji Geun-Eog
Cho Joo-Youn
Hong Kyoung-Sup
|
|
|
Abstract
|
|
|
|
There have been many studies suggesting that probiotics are effective in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). However, its mechanism of action as well as prediction of response is still to be elucidated. In the present study, to find out metabolomic characteristics of probiotic effect in IBS-D, we compared IBS symptom changes and metabolomic characteristics in the subjects’ urine samples between multi-strain probiotics (one strain of Lactobacillus sp. and four strains of Bifidobacterium sp.) group (n?=?32) and placebo group (n?=?31). After 8 weeks’ administration (3 times/day), dissatisfaction in bowel habits and stool frequencies were significantly improved. Also, probiotics group had significantly changed seven metabolites including palmitic acid methyl ester (PAME) and 4,6-dihydroxyquinoline, 4-(2-aminophenyl)-2,4-dioxobutanoic acid (DOBA). According to IBS-SSS and IBS-QoL questionnaires, IBS-SSS responders showed higher PAME levels and IBS-QoL responders showed lower DOBA levels. This suggests potential role of these metabolites as a biomarker to predict probiotics effect in IBS-D patients.
|
|
|
KEYWORD
|
|
|
Irritable bowel syndrome, Probiotics, Metabolomics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|